Brief Title:Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery (CR_KCH)

August 8, 2019 updated by: Volker Burst, University of Cologne

Effect of a Preoperative Calorie Restriction on Renal Function After Cardiac Surgery

The aim of this study is to assess the effect of a diet prior to cardiac surgery on the common postoperative decline of renal function. Until now, there is no known drug or procedure to preserve the kidneys from this impairment. Patients with a known kidney disease are especially at risk. A potential beneficial effect of a diet prior to surgery has been shown in investigations in mammals, therefore this study will investigate if a preoperative diet in patients with known kidney disease and scheduled heart surgery can attenuate or prevent a postoperative loss of kidney function.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Patients with cardiothoracic surgery are at risk for postoperative acute renal failure which is associated with significant morbidity and mortality. There is no drug or procedure known to prevent this loss of renal function. Experimental data suggests, that a preoperative caloric restriction might provide kidney protection in this context. This clinical trial investigates if this phenomenon is also applicable in humans. Patients with a increased risk for a postoperative renal failure due to known chronic kidney disease are randomized in 2 groups. Patients of the diet group receive a calorie restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery). Patients of the control group receive alimentation ad libitum.

Primary objective is the increase of serum creatinine in mg/dl 24 h after induction of ischemia ("cross clamping") in comparison to baseline value obtained in the morning of the day of surgery (day 0) in order to analyse if a preoperative calorie restriction as a preventive strategy leads to a attenuation of postoperative kidney injury. Hypothesis: A seven day calorie restriction reduces the increase of serum creatinine after cardiac surgery in patients with known chronic kidney disease.

Study Type

Interventional

Enrollment (Actual)

82

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cologne, Germany, 50937
        • University of Cologne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Men and women 18 years of age or older
  2. Caucasian origin
  3. Scheduled cardiothoracic operation with employment of cardio-pulmonary bypass and a lead time of 11 days minimum.
  4. Indication for cardiac surgery is determined by the cardiothoracic specialist
  5. Patient and/or legal guardian must be willing and able to give written informed consent
  6. one of the following risk factors:

    1. serum creatinine >1,1 mg/dl in male and > 0,9 mg/dl in female
    2. type 2 diabetes
    3. peripheral artery occlusive disease
    4. heart failure with NYHA III-IV (ejection fraction < 50 %)
    5. combined CABG and heart valve surgery
    6. further surgery after CABG or heart valve surgery

Exclusion Criteria:

  1. End-stage renal disease (patient on dialysis)
  2. Indwelling kidney transplant
  3. Malnutrition (BMI < 18,5 kg/m2)
  4. Body weight < 46 kg in male and < 51 kg in female
  5. BMI > 35 kg/m2 or body weight > 120 kg
  6. Catabolic state (serum albumine < 25 g/l)
  7. Diet within the previous 4 weeks
  8. Inappetence
  9. Weight loss > 1 kg within the previous 2 weeks, if not explained by use of diuretics
  10. Hospital stay during the last 7 days prior to cardiac surgery
  11. Consuming underlying disease
  12. Uncontrolled local or systemic infection
  13. Contraindication for enteral nutrition.
  14. Known allergy against or incompatibility with ingredients of the employed formula-diet
  15. Pregnancy or breast feeding
  16. Participation in other interventional clinical trials.
  17. Missing safe method of contraception or missing occurence of menopause (in female)
  18. Professional or private relationship between subject and the investigators or dependence on the investigators.
  19. Placement in an institution based on official orders.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: control
Ad libitum alimentation
Other: calorie restriction
Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery day 0 corresponds to day of surgery)
Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
Other Names:
  • calorie restriction with Fresubin energy fibre drink

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
The Increase of serum creatinine in mg/dl 24 h after induction of ischemia ("cross clamping") in comparison to baseline value obtained in the morning of the day of surgery (day 0).
Time Frame: baseline and 24 hours after induction of ischemia
baseline and 24 hours after induction of ischemia

Secondary Outcome Measures

Outcome Measure
Time Frame
Urine Neutrophil-Gelatinase associated Lipocalin (NGAL in µg/l) 8h after induction of ischemia in comparison to baseline value obtained in the morning of the day of surgery (day 0).
Time Frame: baseline and 8 hours after induction of ischemia
baseline and 8 hours after induction of ischemia
C-reactive Protein (CRP) 24h after induction of ischemia
Time Frame: baseline and 24 h after induction of ischemia
baseline and 24 h after induction of ischemia
Leucocyte count 24h after induction of ischemia
Time Frame: baseline and 24h after induction of ischemia
baseline and 24h after induction of ischemia
Creatinkinase (CK) 24h after induction of ischemia
Time Frame: baseline and 24 h after induction of ischemia
baseline and 24 h after induction of ischemia
Troponin T 24h after induction of ischemia
Time Frame: baseline and 24 h after induction of ischemia
baseline and 24 h after induction of ischemia
Lactate dehydrogenase 24h after induction of ischemia
Time Frame: baseline and 24 h after ischemia
baseline and 24 h after ischemia
N-terminal pro brain natriuretic peptide (NT-ProBNP) 24h after induction of ischemia
Time Frame: baseline and 24 h after ischemia
baseline and 24 h after ischemia
Serum lactate 24h after induction of ischemia
Time Frame: baseline and 24 hours after ischemia
baseline and 24 hours after ischemia
Maximum increase of serum creatinine within the first 48 h after induction of ischemia
Time Frame: baseline and 48 hours after ischemia
baseline and 48 hours after ischemia
Necessity of renal replacement therapy during hospital stay
Time Frame: pt will be followed for the duration of hospital stay, an expected average of 10 days
pt will be followed for the duration of hospital stay, an expected average of 10 days
In-hospital mortality
Time Frame: pt will be followed for the duration of hospital stay, an expected average of 10 days
pt will be followed for the duration of hospital stay, an expected average of 10 days
Time until fit for discharge
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 10 days
Participants will be followed for the duration of hospital stay, an expected average of 10 days
Length of hospital stay
Time Frame: Pt will be followed for the duration of hospital stay an expected average of 10 days
Pt will be followed for the duration of hospital stay an expected average of 10 days
Echocardiographic estimated left-ventricular ejection fraction as per file, if assessed postoperatively
Time Frame: baseline and postoperatively, expected within 10 days after operation
baseline and postoperatively, expected within 10 days after operation
Occurrence of acute renal failure in accordance with KDIGO I, II, III
Time Frame: Patients will be followed during hospital stay, an expected average of 10 days
Patients will be followed during hospital stay, an expected average of 10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Volker Burst, MD, University of Cologne

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2012

Primary Completion (Actual)

February 1, 2015

Study Completion (Actual)

February 1, 2015

Study Registration Dates

First Submitted

January 30, 2012

First Submitted That Met QC Criteria

February 15, 2012

First Posted (Estimate)

February 16, 2012

Study Record Updates

Last Update Posted (Actual)

August 9, 2019

Last Update Submitted That Met QC Criteria

August 8, 2019

Last Verified

August 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 001 (Buy Pharma Ecza Deposu San. Tic. Ltd.)
  • 00003355 (Registry Identifier: DRKS)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Renal Failure

Clinical Trials on calorie restriction

Subscribe